Roivant Sciences Ltd.
ROIV
Rangering i aksjer
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Aksjekurs
$33.73
Sist synkronisert: 2026-07-31
Markedsverdi
$24.37B
Endring (1 dag)
-2.28%
Endring (1 år)
95.44%
Land
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
EPS for Roivant Sciences Ltd. (ROIV)
EPS per June 2026 TTM: $-0.38
Ifølge de siste økonomiske rapportene og aksjekursen til Roivant Sciences Ltd. er selskapets nåværende EPS (TTM) $-0.38. Ved slutten av 2024 hadde selskapet en EPS på $5.55, en økning sammenlignet med EPS-en i 2023 som var $-1.42.
EPS-historikk for Roivant Sciences Ltd. fra 2020 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $-0.38 | 58.33% |
| 2025 | $-0.24 | -104.32% |
| 2024 | $5.55 | -490.85% |
| 2023 | $-1.42 | 12.70% |
| 2022 | $-1.26 | 6.78% |
| 2021 | $-1.18 | -167.43% |
| 2020 | $1.75 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| $17.32 | -4,657.89% |
US
|
|
| $-7.98 | 2,000.00% |
US
|
|
| $-5.29 | 1,292.11% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -7,400.00% |
NL
|
